Top tier biotech companies are made, not born. That seems to be the message of Enzon Pharmaceuticals Inc. and NPS Pharmaceuticals Inc. , which agreed in late February to combine in a stock-swap transaction valued at approximately $1.6 billion [See Deal]. NPS is the actual acquirer, from an accounting standpoint, but the deal has been variously described as "a merger of equals," "a merger of rivals" and "a merger of opposites."
If the financial markets are having a difficult time understanding the combination—shares of both companies are down about 8% since...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?